George Apostol
Clinical Development Head uniQure
George Apostol has a broad drug development expertise across early, middle and late phases at global development organizations of Eli Lilly, Pfizer, Abbott, Novartis, Shire etc. His main areas of interest have been orphan and pediatric diseases, in particular in CNS and GI therapeutic areas. Over 25 years of pharmaceutical development experience, George has led more than a dozen development programs, established and built multiple R&D teams, published more than 20 articles in peer-reviewed medical journals, and lectured at various scientific events, with a specific focus on rare diseases.
Seminars
Thursday 4th June 2026
Advancing AMT‑162 Gene Therapy for SOD1‑ALS Clinical Progress & Future Opportunities
11:30 am
- Overview of AMT‑162, a one-time intrathecal gene therapy designed to silence SOD1 expression in patients with
- SOD1‑linked ALS and the rationale for targeting this mutation
- Early clinical progress from the Phase I/II EPISOD1 trial, including first patient dosing and favorable independent safety data supporting progression to the second dose cohort
- Key exploratory efficacy and biomarker strategies in the AMT‑162 program, including use of neurofilament light and SOD1 protein levels to assess potential impact on disease progression
- Challenges and opportunities in gene therapy for ALS, including regulatory considerations, patient selection, and the potential for one-time treatment paradigms in rare genetic subtypes
